全文获取类型
收费全文 | 29203篇 |
免费 | 1710篇 |
国内免费 | 197篇 |
学科分类
医药卫生 | 31110篇 |
出版年
2023年 | 207篇 |
2022年 | 176篇 |
2021年 | 735篇 |
2020年 | 465篇 |
2019年 | 580篇 |
2018年 | 694篇 |
2017年 | 612篇 |
2016年 | 789篇 |
2015年 | 890篇 |
2014年 | 1125篇 |
2013年 | 1353篇 |
2012年 | 2118篇 |
2011年 | 2130篇 |
2010年 | 1358篇 |
2009年 | 1271篇 |
2008年 | 1951篇 |
2007年 | 2072篇 |
2006年 | 1810篇 |
2005年 | 1836篇 |
2004年 | 1740篇 |
2003年 | 1607篇 |
2002年 | 1487篇 |
2001年 | 252篇 |
2000年 | 198篇 |
1999年 | 244篇 |
1998年 | 284篇 |
1997年 | 234篇 |
1996年 | 171篇 |
1995年 | 147篇 |
1994年 | 139篇 |
1993年 | 126篇 |
1992年 | 88篇 |
1991年 | 67篇 |
1990年 | 51篇 |
1989年 | 66篇 |
1988年 | 66篇 |
1987年 | 38篇 |
1986年 | 44篇 |
1985年 | 39篇 |
1983年 | 47篇 |
1982年 | 42篇 |
1980年 | 38篇 |
1978年 | 39篇 |
1933年 | 47篇 |
1932年 | 75篇 |
1930年 | 45篇 |
1928年 | 62篇 |
1927年 | 58篇 |
1926年 | 38篇 |
1924年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Elisabeth M Weiss Edith Stadelmann Christian G Kohler Colleen M Brensinger Karen A Nolan Herbert Oberacher Walther Parson Florian Pitterl Harald Niederst?tter Georg Kemmler Hartmann Hinterhuber Josef Marksteiner 《Journal of the International Neuropsychological Society》2007,13(5):881-887
The catechol-O-methyltransferase (COMT) Val158Met polymorphism modulates executive functions and working memory and recent neuroimaging studies implicate an association with emotional processing. We examined the relationship between the COMT Val158Met polymorphism and facial emotion recognition and differentiation in 100 healthy individuals. Compared to Met homozygosity, Val homozygosity was associated with better and faster recognition of negative facial expressions such as anger and sad. Our study provides evidence for a possible influence of the COMT polymorphism on emotion recognition abilities in healthy subjects. Additional research is needed to further define the neurocognitive phenotypes associated with COMT polymorphisms. 相似文献
82.
Daniel Zimpfer Philipp Zrunek Sigrid Sandner Heinz Schima Michael Grimm Andreas Zuckermann Ernst Wolner Georg Wieselthaler 《European journal of cardio-thoracic surgery》2007,31(4):698-702
OBJECTIVE: We have previously shown that fixed pulmonary hypertension in cardiac transplant candidates can be lowered using left ventricular assist devices (LVADs). The post-transplant survival of these patients is uncertain as pulmonary hypertension may reappear, possibly affecting post-transplant survival. MATERIALS AND METHODS: Between 01/2000 and 01/2005 a total of 26 cardiac transplant candidates (92% male; mean age 56.2 years) in whom fixed pulmonary hypertension was lowered by LVAD implantation (pulmonary vascular resistance (PVR) before implantation: 5.1+/-2.8wood units (WU); PVR before cardiac transplantation: 2.0+/-.9WU) underwent cardiac transplantation at our institution. These patients were age and sex matched with 52 cardiac transplant candidates without pulmonary hypertension undergoing cardiac transplantation during the same time period. Study endpoints were peri-transplant complications and long-term survival. Mean follow-up was 36+/-14 months. RESULTS: Peri-transplant mortality was 5% in patients after LVAD therapy and 7% in patients without prior LVAD therapy (p=.089). We observed 2 cases (4%) of acute right heart failure requiring mechanical support in patients without prior LVAD therapy. None of the patients with LVAD therapy developed peri-transplant right heart failure requiring mechanical support. Incidence of other peri-transplant complications was comparable between the two groups. Log-rank (p=.124) revealed comparable long-term survival between patients with (1 year: 85%, 2 year: 85%, 3 year: 85%) and without (1 year: 90%, 2 year 82%, 3 year prior 79%) prior LVAD therapy. CONCLUSION: LVAD therapy lowers fixed pulmonary hypertension in cardiac transplant candidates with fixed pulmonary hypertension. Thereafter, long-term post-transplant survival is comparable to cardiac transplant recipients without pulmonary hypertension. 相似文献
83.
84.
Nikolaus A Haas Christoph K Camphausen 《Pediatric critical care medicine》2006,7(4):399; author reply 399-399; author reply 400
85.
Onnen Grauhan Henryk Siniawski Michael Dandel Hans Lehmkuhl Christoph Knosalla Miralem Pasic Yu-Guo Weng Roland Hetzer 《European journal of cardio-thoracic surgery》2007,32(4):634-638
OBJECTIVE: Due to the shortage of donor hearts, the criteria for organ acceptability have been considerably extended and donor grafts with coronary atherosclerosis are among those offered. This study evaluated whether and to what degree pre-existing coronary atherosclerosis may be acceptable. METHODS: A total of 1253 consecutive HTx recipients were investigated retrospectively for donor-transmitted coronary atherosclerosis (DCAS). Donor-transmitted coronary atherosclerosis was defined as focal atherosclerosis with stenosis of at least 50%. Inclusion criteria were absence of pre-HTx angiogram but performance of angiogram or autopsy within 6 months after heart transplantation. Kaplan-Meier analysis and log-rank test were used. RESULTS: Eighty-five out of 1253 (6.8%) cases were excluded, since coronary evaluation was not performed within 6 months (n=45) or hearts had undergone pre-transplant angiography (n=40). In 1086 patients no donor-transmitted coronary atherosclerosis was found (NDCAS group) and in 82 patients (7%) donor-transmitted coronary atherosclerosis was diagnosed by angiography (n=49) or autopsy (n=33). Single-vessel donor-transmitted coronary atherosclerosis was found in 53/82 patients (DCAS1 group) and double- or triple-vessel donor-transmitted coronary atherosclerosis in 26/82 patients (DCAS2/3 group). Three of the 82 patients with donor-transmitted coronary atherosclerosis were excluded since the autopsy report was unclear regarding degree of atherosclerosis. Early after heart transplantation the 30-day mortality in the NDCAS and DCAS1 groups was 12.2% versus 13.2% whereas in the DCAS2/3 group it was 61.5%. Beyond the first year the annual decrease with and without donor-transmitted coronary atherosclerosis (single-vessel disease) is comparable. CONCLUSIONS: Donor screening without coronary angiogram overlooks significant atherosclerotic lesions in a considerable number of cases (7.0%). Therefore, angiographic donor screening should be performed. Donor grafts with single-vessel coronary atherosclerosis may be accepted as marginal hearts; however, in our opinion, revascularisation (CABG, PTCA) should be considered. Grafts with two- or even three-vessel coronary atherosclerosis seem to have a serious risk for early graft failure. Beyond the first year the outcome of healthy grafts and grafts with donor-transmitted coronary atherosclerosis seems to be comparable. 相似文献
86.
87.
Oberarzt Dr. med. et phil. Georg Oskar Harnapp 《Journal of molecular medicine (Berlin, Germany)》1938,17(11):390-391
Ohne Zusammenfassung 相似文献
88.
89.
Thomas Müller Christoph Erdmann Siegfried Muhlack Dirk Bremen Horst Przuntek Dirk Woitalla 《Journal of clinical neuroscience》2007,14(5):424-428
BACKGROUND: A possible strategy to prolong plasma metabolism of Levodopa/Carbidopa (LD/CD) is Entacapone addition (EN), which improves impaired motor behaviour in patients with Parkinson's disease (PD). AIMS OF THE STUDY: Objectives were to evaluate the clinical response to an increased dopaminergic substitution with EN by clinical rating and assessment of complex motions and to investigate the change of movement in PD patients during repeat drug administration during an eight hour interval. METHODS: We used peg insertion with a computer based device and clinical rating for assessment of motor function in 20 treated PD patients. They received LD/CD and then the same LD/CD dosage plus EN in a standardised, open label fashion. RESULTS: Motor scores and performance of the instrumental task were significantly better and the fluctuation of movement was less intense during the LD/CD/EN condition according to the motor test outcomes. CONCLUSION: EN supplementation improves motor symptoms and provides a more continuous movement behaviour in PD patients. 相似文献
90.
Markus Thalmann Heinrich Schima Georg Wieselthaler Ernst Wolner 《The Journal of heart and lung transplantation》2005,24(3):237-245
The beating heart and the resultant pulse wave have been a symbol of life for centuries. The development history of roller pumps for cardiopulmonary bypass shows that the human body tolerates non-pulsatile blood flow, at least for short-term support. Over the last few years, many types of rotary blood pumps have been developed for clinical use in patients requiring mid- to long-term support. Although early clinical experiences in patients with long-term support have been promising, the matter of whether pulsatile flow is needed or not remains controversial. Therefore, this review summarizes the observed clinical consequences of continuous blood flow in patients supported by rotary blood pumps and relates these consequences to underlying experimental studies. 相似文献